Becker's Healthcare January 24, 2025
Alexandra Murphy

AbbVie has entered a collaboration with Neomorph to develop molecular glue degraders for oncology and immunology.

Molecular glue degraders are a class of small molecules designed to selectively degrade proteins that contribute to disease, including those involved in cancer growth and immune system dysfunction, according to a Jan. 23 news release from the drugmaker.

...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma / Biotech
Which Biopharma Startups Made the Cut for INVEST Pitch Perfect?
PBMs push private-label biosimilars in 2025 formularies
CAR T-Cell Pioneer Plots Technology’s Next Steps
Eli Lilly Adds Alzheimer’s Care to Digital Health Platform Services
GLP-1 drug use for weight loss has soared, costing billions

Share This Article